- Home
- AZTA vs LXP Comparison
AZTA vs LXP Comparison
Compare AZTA & LXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AZTA
- LXP
- Stock Information
- Founded
- AZTA 1978
- LXP 1993
- Country
- AZTA United States
- LXP United States
- Employees
- AZTA N/A
- LXP N/A
- Industry
- AZTA Industrial Machinery/Components
- LXP Real Estate Investment Trusts
- Sector
- AZTA Technology
- LXP Real Estate
- Exchange
- AZTA Nasdaq
- LXP Nasdaq
- Market Cap
- AZTA 1.8B
- LXP N/A
- IPO Year
- AZTA 1995
- LXP 1993
- Fundamental
- Price
- AZTA $31.30
- LXP $8.33
- Analyst Decision
- AZTA Buy
- LXP Buy
- Analyst Count
- AZTA 4
- LXP 3
- Target Price
- AZTA $58.75
- LXP $11.50
- AVG Volume (30 Days)
- AZTA 712.7K
- LXP 2.3M
- Earning Date
- AZTA 05-07-2025
- LXP 05-01-2025
- Dividend Yield
- AZTA N/A
- LXP 6.47%
- EPS Growth
- AZTA N/A
- LXP 59.02
- EPS
- AZTA N/A
- LXP 0.13
- Revenue
- AZTA $662,108,000.00
- LXP $358,458,000.00
- Revenue This Year
- AZTA N/A
- LXP N/A
- Revenue Next Year
- AZTA $5.44
- LXP $8.16
- P/E Ratio
- AZTA N/A
- LXP $64.15
- Revenue Growth
- AZTA 5.36
- LXP 5.27
- 52 Week Low
- AZTA $31.09
- LXP $7.65
- 52 Week High
- AZTA $63.58
- LXP $10.57
- Technical
- Relative Strength Index (RSI)
- AZTA 25.75
- LXP 37.06
- Support Level
- AZTA $33.33
- LXP $8.56
- Resistance Level
- AZTA $35.80
- LXP $8.77
- Average True Range (ATR)
- AZTA 1.78
- LXP 0.18
- MACD
- AZTA -0.11
- LXP -0.06
- Stochastic Oscillator
- AZTA 2.42
- LXP 1.33
About AZTA Azenta Inc.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.